InMode Ltd. (NASDAQ:INMD) Shares Sold by DDD Partners LLC

DDD Partners LLC lessened its position in shares of InMode Ltd. (NASDAQ:INMD - Free Report) by 46.3% in the 4th quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 606,965 shares of the healthcare company's stock after selling 522,863 shares during the period. DDD Partners LLC owned about 0.72% of InMode worth $10,136,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Systematic Financial Management LP lifted its position in shares of InMode by 13.3% during the 3rd quarter. Systematic Financial Management LP now owns 982,111 shares of the healthcare company's stock worth $16,647,000 after buying an additional 115,492 shares during the last quarter. Barclays PLC lifted its position in shares of InMode by 113.5% during the 3rd quarter. Barclays PLC now owns 169,630 shares of the healthcare company's stock worth $2,876,000 after buying an additional 90,173 shares during the last quarter. Hotchkis & Wiley Capital Management LLC lifted its position in shares of InMode by 12.9% during the 3rd quarter. Hotchkis & Wiley Capital Management LLC now owns 720,750 shares of the healthcare company's stock worth $12,217,000 after buying an additional 82,100 shares during the last quarter. State Street Corp lifted its position in shares of InMode by 3.7% during the 3rd quarter. State Street Corp now owns 2,044,640 shares of the healthcare company's stock worth $34,657,000 after buying an additional 73,183 shares during the last quarter. Finally, Quantbot Technologies LP purchased a new stake in shares of InMode during the 3rd quarter worth approximately $1,104,000. Institutional investors and hedge funds own 68.04% of the company's stock.

Wall Street Analysts Forecast Growth

Several brokerages have recently weighed in on INMD. Needham & Company LLC restated a "hold" rating on shares of InMode in a research report on Tuesday, February 4th. Barclays upped their price target on shares of InMode from $26.00 to $29.00 and gave the company an "overweight" rating in a research report on Wednesday, February 5th. Three equities research analysts have rated the stock with a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, the company presently has an average rating of "Hold" and an average price target of $22.25.

InMode Trading Down 2.2 %

INMD stock traded down $0.43 on Thursday, hitting $18.97. The company's stock had a trading volume of 599,522 shares, compared to its average volume of 910,324. The firm has a 50 day moving average of $17.38 and a two-hundred day moving average of $17.28. InMode Ltd. has a 1 year low of $14.87 and a 1 year high of $23.46. The stock has a market cap of $1.32 billion, a price-to-earnings ratio of 8.07 and a beta of 2.13.

About InMode

InMode Ltd. designs, develops, manufactures, and markets minimally invasive aesthetic medical products based on its proprietary radiofrequency assisted lipolysis and deep subdermal fractional radiofrequency technologies in the United States and internationally. The company offers minimally invasive aesthetic medical products for various procedures, such as liposuction with simultaneous skin tightening, body and face contouring, and ablative skin rejuvenation treatments, as well as for use in women's health conditions and procedures.